Rystiggo is the first therapy for both subtypes of the rare disease, caused by pathological auto-antibodies that attack neuromuscular junctions and, like Zilbrysq, can be administered subcutaneously.

Generalized myasthenia gravis (gMG) affects most patients through a handful of well-characterized neuromuscular junction ...

There has been some debate about whether more frequent subcutaneous injections will trump less frequent intravenous infusions in gMG, so all eyes will be on the take-up of Rystiggo and Zilbrysq ...

BIMZELX ®, EVENITY ®, FINTEPLA ®, RYSTIGGO ® and ZILBRYSQ ® as well as solid contribution from CIMZIA ® and BRIVIACT ® reaching its peak sales two years ahead of target Underlying ...

Five new agents to treat gMG have been approved, including three complement inhibitors -- eculizumab (Soliris), ravulizumab (Ultomiris), and zilucoplan (Zilbrysq) – and two neonatal FcRn ...

In 2023, the US Food and Drug Administration approved Rystiggo and Zilbrysq for the treatment of adults with generalized myasthenia gravis. UCB acquired Zilbrysq through its acquisition of Ra ...